Advertisement

Topics

GSK Presents Positive Results From Phase III Study On Shingrix

10:07 EDT 21 Jun 2017 | FinanzNachrichten

LONDON (dpa-AFX) - GlaxoSmithKline PLC (GSK.L, GSK) said it will present new results from a clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in peop...

Original Article: GSK Presents Positive Results From Phase III Study On Shingrix

NEXT ARTICLE

More From BioPortfolio on "GSK Presents Positive Results From Phase III Study On Shingrix"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...